DE69925496D1 - In-vitro verfahren zur verwendung von zot oder zonulin zur inhibierung der lymphozyten proliferation in einer antigen-spezifischen weise - Google Patents

In-vitro verfahren zur verwendung von zot oder zonulin zur inhibierung der lymphozyten proliferation in einer antigen-spezifischen weise

Info

Publication number
DE69925496D1
DE69925496D1 DE69925496T DE69925496T DE69925496D1 DE 69925496 D1 DE69925496 D1 DE 69925496D1 DE 69925496 T DE69925496 T DE 69925496T DE 69925496 T DE69925496 T DE 69925496T DE 69925496 D1 DE69925496 D1 DE 69925496D1
Authority
DE
Germany
Prior art keywords
antigen
zot
zonulin
vitro method
specific way
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69925496T
Other languages
English (en)
Other versions
DE69925496T2 (de
Inventor
Alessio Fasano
B Sztein
Ruiliang Lu
K Tanner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of DE69925496D1 publication Critical patent/DE69925496D1/de
Application granted granted Critical
Publication of DE69925496T2 publication Critical patent/DE69925496T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69925496T 1998-09-14 1999-09-09 In-vitro verfahren zur verwendung von zot oder zonulin zur inhibierung der lymphozyten proliferation in einer antigen-spezifischen weise Expired - Fee Related DE69925496T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10026698P 1998-09-14 1998-09-14
US100266P 1998-09-14
PCT/US1999/018842 WO2000015252A1 (en) 1998-09-14 1999-09-09 Method of using zot or zonulin to inhibit lymphocyte proliferation in an antigen-specific manner

Publications (2)

Publication Number Publication Date
DE69925496D1 true DE69925496D1 (de) 2005-06-30
DE69925496T2 DE69925496T2 (de) 2006-02-02

Family

ID=22278888

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69925496T Expired - Fee Related DE69925496T2 (de) 1998-09-14 1999-09-09 In-vitro verfahren zur verwendung von zot oder zonulin zur inhibierung der lymphozyten proliferation in einer antigen-spezifischen weise

Country Status (17)

Country Link
EP (1) EP1113813B1 (de)
JP (1) JP2002524531A (de)
KR (1) KR100615442B1 (de)
CN (1) CN1228084C (de)
AT (1) ATE296110T1 (de)
AU (1) AU754142B2 (de)
CA (1) CA2342771A1 (de)
DE (1) DE69925496T2 (de)
ES (1) ES2239480T3 (de)
HU (1) HUP0103965A3 (de)
IL (2) IL141563A0 (de)
MX (1) MXPA01002600A (de)
NO (1) NO20011253L (de)
NZ (2) NZ510150A (de)
RU (1) RU2214271C2 (de)
WO (1) WO2000015252A1 (de)
ZA (1) ZA200102071B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
EP2062909A1 (de) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Herstellung von Peptiden und Reinigungsverfahren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions

Also Published As

Publication number Publication date
NZ521410A (en) 2005-06-24
ATE296110T1 (de) 2005-06-15
CN1317975A (zh) 2001-10-17
EP1113813A1 (de) 2001-07-11
ZA200102071B (en) 2002-02-25
AU6019099A (en) 2000-04-03
EP1113813A4 (de) 2002-05-29
NZ510150A (en) 2002-10-25
AU754142B2 (en) 2002-11-07
IL141563A0 (en) 2002-03-10
RU2214271C2 (ru) 2003-10-20
NO20011253L (no) 2001-03-15
CN1228084C (zh) 2005-11-23
DE69925496T2 (de) 2006-02-02
KR100615442B1 (ko) 2006-08-25
ES2239480T3 (es) 2005-09-16
MXPA01002600A (es) 2002-04-08
IL141563A (en) 2006-06-11
HUP0103965A3 (en) 2004-06-28
NO20011253D0 (no) 2001-03-13
JP2002524531A (ja) 2002-08-06
KR20010075114A (ko) 2001-08-09
EP1113813B1 (de) 2005-05-25
CA2342771A1 (en) 2000-03-23
HUP0103965A2 (hu) 2002-03-28
WO2000015252A1 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
DK0975359T3 (da) Anvendelse af forbindelser, der binder en cytoplasmisk dipeptidase til synergistisk virkning af immunreaktionen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
MX9205240A (es) Composicion y metodo para tratar hepatitis c.
DE69623970D1 (de) Formulierung von d-threo methylphenidat mit verzögerter freisetzung
AU2947292A (en) Device for controlling bird nuisances
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
ATE233557T1 (de) Verwendung von konjugiertes linolensäure zur steigerung der aktivität von natural killer- lymphozyten
DE69728294D1 (de) Substance p behandlung zur immunostimulierung
DE69925496D1 (de) In-vitro verfahren zur verwendung von zot oder zonulin zur inhibierung der lymphozyten proliferation in einer antigen-spezifischen weise
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
ATE334193T1 (de) Verfahren zur reduzierung von spezifischen immunreaktionen
ATE98872T1 (de) Antagonist fuer interleukin-5 zur verhuetung oder verminderung von eosinophilie.
ATE236650T1 (de) Verfahren zur hemmung der phagozytose
DE60334499D1 (de) Verfahren zur erhöhung der ausbreitung von b-zellen
DE69941896D1 (de) Kontrolle der verfügbarkeit oder aktivität der proteine durch verwendung von protease-inhibitoren oder rezeptor-fragmenten
DE69534118D1 (de) Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene
ATE210989T1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
DE69938827D1 (de) Verwendung von inhibitoren von asparaginyl-endopeptidase aus säugetieren zur modulierung des immunsystemen
DE68905777D1 (de) Verfahren und gleitschutzunterlage zur verhinderung des wanderns von matten oder aehnlichen kleinen teppichen.
ATE287538T1 (de) Verfahren zur immunchemischen quantifizierung von inaktivierten, immunreaktiven antigenen
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
DE69112392D1 (de) Bcrf1-antagonisten zur behandlung von epstein-barr-virus-infektionen.
DE602004013291D1 (de) Dendritische zelle mit alpha-glycosylceramid-derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen
ES1008386U (es) Herramienta apretadora para la colocacion de baldosas adyacentes de moqueta o revestimiento similar.
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee